| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8926256 | Gynécologie Obstétrique Fertilité & Sénologie | 2018 | 8 Pages |
Abstract
Dienogest is recommended as second-line therapy for the management of painful endometriosis (Grade B). Because of lack of evidence, aromatase inhibitors, elagolix, SERM, SPRM and anti-TNF-α are not recommended for the management of painful endometriosis (Grade C).
Keywords
MifepristoneDienogestAnti-angiogenic treatmentAgonistes de la GnRHEndometrioseGnRH agonistsEndometriosisselective progesterone receptor modulatorsMedical treatmenttraitement médicalAnti-TNF alphaSelective estrogen receptor modulatorsAromatase inhibitorsMatrix metalloproteinase inhibitorsInhibiteurs de l’aromatase
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
G. Legendre, L. Delbos, E. Hudon, N. Chabbert-Buffet, S. Geoffron, M. Sauvan, H. Fernandez, P.-E. Bouet, P. Descamps,